Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial

Libby, 2005, The forgotten majority: unfinished business in cardiovascular risk reduction., J Am Coll Cardiol, 46, 1225, 10.1016/j.jacc.2005.07.006

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies., Circulation, 79, 8, 10.1161/01.CIR.79.1.8

Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events., N Engl J Med, 357, 1301, 10.1056/NEJMoa064278

Nicholls, 2005, Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits., Arterioscler Thromb Vasc Biol, 25, 2416, 10.1161/01.ATV.0000184760.95957.d6

Badimon, 1990, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit., J Clin Invest, 85, 1234, 10.1172/JCI114558

Badimon, 1989, High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits., Lab Invest, 60, 455

Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy., N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

Keene, 2014, Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients., BMJ, 349, g4379, 10.1136/bmj.g4379

Toth, 2014, Should low high-density lipoprotein cholesterol (HDL-C) be treated?, Best Pract Res Clin Endocrinol Metab, 28, 353, 10.1016/j.beem.2013.11.002

Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients., N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus., N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282

Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial., Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2

Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial., JAMA, 290, 2292, 10.1001/jama.290.17.2292

Tardy, 2014, CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice., Atherosclerosis, 232, 110, 10.1016/j.atherosclerosis.2013.10.018

Tardy, 2015, HDL and CER-001 inverse-dose dependent inhibition of atherosclerotic plaque formation in apoE-/- mice: evidence of ABCA1 down-regulation., PLoS One, 10, e0137584, 10.1371/journal.pone.0137584

Tardif, 2014, Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial., Eur Heart J, 35, 3277, 10.1093/eurheartj/ehu171

Kootte, 2015, Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA., J Lipid Res, 56, 703, 10.1194/jlr.M055665

Hovingh, 2015, The effect of an apolipoprotein A-I–containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study., Am Heart J, 169, 736, 10.1016/j.ahj.2015.01.008

Kataoka, Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden., Cardiovasc Diag Ther

Andrews, 2017, Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study., Cardiovasc Diagn Ther, 7, 45, 10.21037/cdt

Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial., JAMA, 291, 1071, 10.1001/jama.291.9.1071

Nissen, 2006, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial., JAMA, 295, 1556, 10.1001/jama.295.13.jpc60002

Nissen, 2008, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial., JAMA, 299, 1561, 10.1001/jama.299.13.1561

Nissen, 2008, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial., JAMA, 299, 1547, 10.1001/jama.299.13.1547

Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis., N Engl J Med, 356, 1304, 10.1056/NEJMoa070635

Nissen, 2006, Effect of ACAT inhibition on the progression of coronary atherosclerosis., N Engl J Med, 354, 1253, 10.1056/NEJMoa054699

Nissen, 2004, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial., JAMA, 292, 2217, 10.1001/jama.292.18.2217

Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease., N Engl J Med, 365, 2078, 10.1056/NEJMoa1110874

Nicholls, 2016, Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial., JAMA, 316, 2373, 10.1001/jama.2016.16951

Bowman, 2017, Effects of anacetrapib in patients with atheroscl, N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study., Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2

Besler, 2011, Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease., J Clin Invest, 121, 2693, 10.1172/JCI42946

Chalmers, 2017, Nonlinear dynamics of early atherosclerotic plaque formation may determine the efficacy of high density lipoproteins (HDL) in plaque regression., PLoS One, 12, e0187674, 10.1371/journal.pone.0187674

Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis., N Engl J Med, 364, 127, 10.1056/NEJMoa1001689

Gibson, 2016, Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): a phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction., Am Heart J, 180, 22, 10.1016/j.ahj.2016.06.017

Barter, 2004, Antiinflammatory properties of HDL., Circ Res, 95, 764, 10.1161/01.RES.0000146094.59640.13

Atkinson, 1989, An Introduction to Numerical Analysis, 2nd ed